![Cancers | Free Full-Text | Recurrence Risk after Radical Colorectal Cancer Surgery—Less Than before, But How High Is It? Cancers | Free Full-Text | Recurrence Risk after Radical Colorectal Cancer Surgery—Less Than before, But How High Is It?](https://www.mdpi.com/cancers/cancers-12-03308/article_deploy/html/images/cancers-12-03308-g001.png)
Cancers | Free Full-Text | Recurrence Risk after Radical Colorectal Cancer Surgery—Less Than before, But How High Is It?
![Long-term outcomes after complete mesocolic excision for colon cancer at a tertiary care center in Saudi Arabia | Annals of Saudi Medicine Long-term outcomes after complete mesocolic excision for colon cancer at a tertiary care center in Saudi Arabia | Annals of Saudi Medicine](https://www.annsaudimed.net/cms/asset/f3b90a8b-897d-4dba-8590-6c14fe59bf83/asm-3-207.jpg)
Long-term outcomes after complete mesocolic excision for colon cancer at a tertiary care center in Saudi Arabia | Annals of Saudi Medicine
![Advanced Age Is a Risk Factor for Recurrence After Resection in Stage II Colorectal Cancer | In Vivo Advanced Age Is a Risk Factor for Recurrence After Resection in Stage II Colorectal Cancer | In Vivo](https://iv.iiarjournals.org/content/invivo/34/1/339/F1.large.jpg)
Advanced Age Is a Risk Factor for Recurrence After Resection in Stage II Colorectal Cancer | In Vivo
![HIPEC OVHIPEC chemotherapy ovarian cancer of the ovary debulking recurrence surgery operation intervention treament therapy stage 2 stage 3 stage 4 stage II stage III stage IV recurrent surgical center centers HIPEC OVHIPEC chemotherapy ovarian cancer of the ovary debulking recurrence surgery operation intervention treament therapy stage 2 stage 3 stage 4 stage II stage III stage IV recurrent surgical center centers](https://www.drmulier.com/uitgezaaide%20ovariumkanker%20en.jpg)
HIPEC OVHIPEC chemotherapy ovarian cancer of the ovary debulking recurrence surgery operation intervention treament therapy stage 2 stage 3 stage 4 stage II stage III stage IV recurrent surgical center centers
![Inferior oncological prognosis of surgery without oral chemotherapy for stage III colon cancer in clinical settings | World Journal of Surgical Oncology | Full Text Inferior oncological prognosis of surgery without oral chemotherapy for stage III colon cancer in clinical settings | World Journal of Surgical Oncology | Full Text](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2F1477-7819-12-145/MediaObjects/12957_2014_Article_1631_Fig1_HTML.jpg)
Inferior oncological prognosis of surgery without oral chemotherapy for stage III colon cancer in clinical settings | World Journal of Surgical Oncology | Full Text
![Molecular Markers Identify Subtypes of Stage III Colon Cancer Associated With Patient Outcomes - ScienceDirect Molecular Markers Identify Subtypes of Stage III Colon Cancer Associated With Patient Outcomes - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0016508514012013-gr3.jpg)
Molecular Markers Identify Subtypes of Stage III Colon Cancer Associated With Patient Outcomes - ScienceDirect
![PDF] High Risk Stage 2 and Stage 3 Colon Cancer, Predictors of Recurrence and Effect of Adjuvant Therapy in a Nonselected Population | Semantic Scholar PDF] High Risk Stage 2 and Stage 3 Colon Cancer, Predictors of Recurrence and Effect of Adjuvant Therapy in a Nonselected Population | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/924dcf6ba539d31ea808e6e522d135081883cc9e/4-Figure2-1.png)
PDF] High Risk Stage 2 and Stage 3 Colon Cancer, Predictors of Recurrence and Effect of Adjuvant Therapy in a Nonselected Population | Semantic Scholar
![Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial - The Lancet Gastroenterology & Hepatology Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial - The Lancet Gastroenterology & Hepatology](https://www.thelancet.com/cms/attachment/00312b86-330c-4d9b-9e07-981f7e10a581/gr1.gif)
Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial - The Lancet Gastroenterology & Hepatology
![Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials - The Lancet Oncology Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials - The Lancet Oncology](https://www.thelancet.com/cms/asset/c3854be2-2dc4-485e-80d5-acd23e1c3b90/gr1.jpg)
Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials - The Lancet Oncology
![Cumulative incidence of recurrence rates by tumor site and DNA mismatch... | Download Scientific Diagram Cumulative incidence of recurrence rates by tumor site and DNA mismatch... | Download Scientific Diagram](https://www.researchgate.net/publication/51150859/figure/fig2/AS:276956890320899@1443043076273/Cumulative-incidence-of-recurrence-rates-by-tumor-site-and-DNA-mismatch-repair-MMR.png)
Cumulative incidence of recurrence rates by tumor site and DNA mismatch... | Download Scientific Diagram
![PDF] High Risk Stage 2 and Stage 3 Colon Cancer, Predictors of Recurrence and Effect of Adjuvant Therapy in a Nonselected Population | Semantic Scholar PDF] High Risk Stage 2 and Stage 3 Colon Cancer, Predictors of Recurrence and Effect of Adjuvant Therapy in a Nonselected Population | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/924dcf6ba539d31ea808e6e522d135081883cc9e/2-Figure1-1.png)
PDF] High Risk Stage 2 and Stage 3 Colon Cancer, Predictors of Recurrence and Effect of Adjuvant Therapy in a Nonselected Population | Semantic Scholar
![Prevention of Colon Cancer Recurrence From Minimal Residual Disease: Computer Optimized Dose Schedules of Intermittent Apoptotic Adjuvant Therapy | JCO Clinical Cancer Informatics Prevention of Colon Cancer Recurrence From Minimal Residual Disease: Computer Optimized Dose Schedules of Intermittent Apoptotic Adjuvant Therapy | JCO Clinical Cancer Informatics](https://ascopubs.org/cms/10.1200/CCI.20.00016/asset/images/large/cci.20.00016f3.jpeg)
Prevention of Colon Cancer Recurrence From Minimal Residual Disease: Computer Optimized Dose Schedules of Intermittent Apoptotic Adjuvant Therapy | JCO Clinical Cancer Informatics
![Hazard rate of tumor recurrence over time in patients with colon cancer: implications for postoperative surveillance from three Japanese Foundation for Multidisciplinary Treatment of Cancer (JFMC) clinical trials Hazard rate of tumor recurrence over time in patients with colon cancer: implications for postoperative surveillance from three Japanese Foundation for Multidisciplinary Treatment of Cancer (JFMC) clinical trials](https://www.jcancer.org/ms/getimage.php?name=jcav08p4057g002.jpg)
Hazard rate of tumor recurrence over time in patients with colon cancer: implications for postoperative surveillance from three Japanese Foundation for Multidisciplinary Treatment of Cancer (JFMC) clinical trials
![Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer | International Journal of Clinical Oncology Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer | International Journal of Clinical Oncology](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs10147-019-01485-z/MediaObjects/10147_2019_1485_Fig9_HTML.png)